Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | BCHE known ✓ | P06276 | 2/20 | 0.45 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.45 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.45 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.43 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 2/20 | 0.66 |
| ▸ | RAC1 | P63000 | 5/20 | 0.60 |
| ▸ | CDC42 | P60953 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL424548 | 0.99 | RAD52 (0.67) | RAD52RAC1CDC42MAPTMCL1 | |
| Hydrochloric Acid SCHEMBL29546268 | 0.99 | RAD52 (0.67) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL424549 | 0.97 | RAD52 (0.69) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL13839324 | 0.89 | RAD52 (0.81) | RAD52RAC1CDC42MAPTMCL1 | |
| Hydrochloric Acid SCHEMBL8709312 | 0.83 | RAC1 (0.70) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL17029135 | 0.82 | RAD52 (0.71) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL9679413 | 0.82 | RAC1 (0.69) | RAD52RAC1CDC42MAPTMCL1 | |
| Hydrochloric Acid SCHEMBL8709205 | 0.81 | RAC1 (0.70) | RAD52RAC1CDC42MAPTMCL1 | |
| Nitidine SCHEMBL164193 | 0.80 | BCL2L1 (0.76) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL15413681 | 0.80 | RAC1 (0.71) | RAD52RAC1CDC42MAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-10725042-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10722530-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIV CASE WESTERN RESERVE (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| EP-2173333-B1 | COMBINATIONS OF ANTIFOLATE AGENT AND METHOXYAMINE IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017176756-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-9498489-B2 | Antimetabolite agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| CN-104958299-A | Antifolate agent combinations in the treatment of cancer | TRACON PHARMACEUTICALS INC | 2015-10-07 | — | — | CN | disclosed |
| US-8017618-B2 | Administering antifolate anticancer agent and methoxyamine to enhance or increase the effect of the antifolate anticancer agent | TRACON PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| CN-102014887-A | Combined use of antifolates in cancer treatment | TRACON | 2011-04-13 | — | — | CN | disclosed |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| EP-2173333-A2 | COMBINATIONS OF ANTIFOLATE AGENT AND METHOXYAMINE IN THE TREATMENT OF CANCER | Tracon Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-1123099-B1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008083107-A2 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | TRACON (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| WO-2003070234-A9 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003070234-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241186-A1 | Alkylating agent combinations in the treatment of cancer | UNG, TOP2A, OGG1 | ABL1 2177/4885GAA 1700/4885BCHE 2898/4885 |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | ABL1 3807/4885GAA 108/4885BCHE 264/4885 |
| US-10722530-B2 | Methods of diagnosing and treating cancer | UNG, TP53, OGG1 | ABL1 3856/4885GAA 318/4885BCHE 754/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | ABL1 3856/4885GAA 318/4885BCHE 754/4885 |
| US-20080234298-A1 | ANTIFOLATE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | FEN1, UNG, FOLR1 | ABL1 3833/4885GAA 1612/4885BCHE 2522/4885 |
| US-20190117663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PARP2, PARP1, PPP2CA | ABL1 1364/4885GAA 1406/4885BCHE 3270/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | ABL1 3807/4885GAA 108/4885BCHE 264/4885 |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | UNG, OGG1, MPG | ABL1 3870/4885GAA 238/4885BCHE 1474/4885 |
| US-10725042-B2 | Methods of diagnosing and treating cancer | UNG, NTPCR, GUSB | ABL1 3071/4885GAA 749/4885BCHE 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.